F.A.Q.
FAQ
Frequently Asked Questions
Myelotracker is a peptide, so it may be degraded in the presence of living cells or after injection in animals or humans?
Myelotacker+ is a proteolysis-resistant derivative of Myelotracker. It has been successfully used with living cells (live microscopy) and in animal models of inflammation. See Anderson et al, 2018 for further informations.
What is Myelotracker toxicity in mice?
A proper toxicity study is on going. For now, no toxicity has been reported upon injection of 5 microg/mouse (after 48h).
Radiolabeled 18F-FDG is used for PET-scan imaging of tumors. What is the benefit of using Myelotracker?
18F-fluorodeoxyglucose (18F-FDG) allows the detection of tumors and metastasis based on their hypoxic microenvironment and their glycolytic metabolism. No information regarding their inflammatory status is provided with this marker.
Other radiotracers are used to image inflammatory sites. What is advantage of Myelotracker?
That is correct, although no inflammatory marker allows the specific detection of neutrophil secretion at inflamed sites, which can be done with Myelotracker.
Among others, some markers bind to neutrophil cell-surface exposed targets (e.g. FPR, TSPO), which do not give information regarding their secretion activity. Other markers bind to proteins expressed and secreted by neutrophils (e.g. MMPs) but not only.
